Cellectis Q2 2024 Earnings Report

Cellectis EPS Results

• Actual EPS: -$0.28
• Consensus EPS: -$0.33
• Beat/Miss: Beat by +$0.05
• One Year Ago EPS: N/A

Cellectis Revenue Results

• Actual Revenue: $9.50 million
• Expected Revenue: $6.00 million
• Beat/Miss: Beat by +$3.50 million
• YoY Revenue Growth: N/A

Cellectis Announcement Details

• Quarter: Q2 2024
• Date: 8/6/2024
• Time: N/A

Cellectis (NASDAQ:CLLS), a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.